<SEC-DOCUMENT>0001193125-13-329144.txt : 20130809
<SEC-HEADER>0001193125-13-329144.hdr.sgml : 20130809
<ACCEPTANCE-DATETIME>20130809160300
ACCESSION NUMBER:		0001193125-13-329144
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130809
DATE AS OF CHANGE:		20130809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		131026525

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206.676.5000

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d581986d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, DC 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;9, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>OMEROS CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Washington</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-34475</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>91-1663741</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>201 Elliott Avenue West </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Seattle, Washington 98119 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices,
including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(206) 676-5000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name
or former address, if changed since last report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02 Results of Operation and Financial Condition. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;9, 2013, Omeros Corporation issued a press release announcing financial results for the three and six months ended
June&nbsp;30, 2013. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be &#147;filed&#148; for
purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in
the accompanying exhibit shall not be incorporated by reference into any filing with the United States Securities and Exchange Commission made by Omeros Corporation, whether made before or after the date hereof, regardless of any general
incorporation language in such filing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated August 9, 2013 relating to Omeros&#146; financial results for the three and six months ended June 30, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OMEROS CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;/s/ Gregory A. Demopulos</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory A. Demopulos, M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">and Chairman of the Board of Directors</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;9, 2013 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated August 9, 2013 relating to Omeros&#146; financial results for the three and six months ended June 30, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d581986dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g581986image-header.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Omeros Corporation Reports Second Quarter 2013 Financial Results </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Seattle, WA &#150; August&nbsp;9, 2013</B>&#150; Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to
discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Results </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating
expenses for the quarter ended June&nbsp;30, 2013 were $13.3 million and included non-cash expenses of $2.1 million related to rent expense and stock-based compensation. For the same period in 2012, total operating expenses were $9.8 million, which
included non-cash rent and stock-based compensation expenses of $569,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The increase in total operating expenses for the quarter ended June
30, 2013 is primarily due to expenses related to advancing our MASP-2 program toward the clinic, the non-cash rent expense and stock-based compensation discussed above, preparing the NDA and MAA for OMS302, the planned commercial launch of OMS302 in
2014, and conducting our Phase 1 clinical program evaluating OMS824. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of our OMS302 Phase 3 clinical program in January 2013 and the
completion of our first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue for the
quarter ended June 30, 2013 was $140,000 compared to $1.5 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company&#146;s GPCR platform development funding agreement with Vulcan Inc. and its
affiliate. While research continues under the company&#146;s GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the quarter ended June 30, 2013, Omeros reported a net loss of $13.6 million, or $0.48 per share, inclusive of the above-referenced $2.1 million of non-cash charges, compared to a net loss of $8.5
million, or $0.38 per share, inclusive of the above-referenced $569,000 of non-cash charges, for the same period in 2012. At June 30, 2013, Omeros had cash, cash equivalents and short-term investments of $20.1 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We continue to make significant progress in advancing Omeros along the path to commercialization,&#148; said Gregory A. Demopulos, M.D., chairman
and chief executive officer of Omeros. &#147;We submitted an NDA to the FDA for OMS302, a major milestone in our plans to bring the first of our products to market, and we remain on track to submit an MAA to the European regulators later this
quarter. Our Phase 1 OMS824 clinical program generated positive results, demonstrating a high level of target occupancy without the movement-related side effects exhibited by other PDE10 inhibitors, and we plan to begin a Phase 2 trial in patients
with Huntington&#146;s disease in the fourth quarter. In July, we initiated enrollment in our Phase 1 clinical program for OMS721, further expanding our clinical franchise. We expect continued successes across our pipeline over the remainder of the
year as we prepare for a 2014 market launch of OMS302.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Second Quarter and Recent Highlights </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Announced submission of a New Drug Application, or NDA, to the FDA for approval of OMS302 for use in patients undergoing intraocular lens replacement
surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros&#146; proprietary PharmacoSurgery&#153; product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation
resulting from cataract and other lens replacement surgery. The submission was supported by the positive results from two pivotal Phase 3 trials that enrolled both cataract surgery and refractive lens exchange patients. In these trials, OMS302
demonstrated statistically significant superiority over placebo in maintenance of intraoperative mydriasis, prevention of surgically induced miosis and reduction of postoperative pain. Omeros intends to submit a Marketing Authorization Application,
or MAA, to the European Medicines Agency, or EMA, in the third quarter of 2013, seeking approval for the Company to market and sell OMS302 in the European Union. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reported positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. This
study measured the extent to which OMS824 binds to PDE10 in the basal ganglia, a region of the brain that has been linked to a wide range of diseases that affect cognition. The results of this study showed that the selected dose of OMS824 achieved
an average of approximately 50 percent (with a high of approximately 70 percent) occupancy of PDE10 without triggering the extrapyramidal symptoms (e.g., loss of muscle control, muscle rigidity, tremors, or involuntary muscle movements) reported as
side effects with other PDE10 inhibitors that achieved similar or significantly lower occupancy levels. Omeros plans to advance OMS824 into Phase 2 clinical trials for Huntington&#146;s disease and for schizophrenia later this year. The OMS824 IND
for use in patients has already been cleared by the FDA for use in both patient populations. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Announced positive data using OMS721, the lead human monoclonal antibody in Omeros&#146; mannan-binding lectin-associated serine protease-2 (MASP-2)
program, in a well-established animal model of thrombotic microangiopathy (TMA). Thrombotic microangiopathies represent a group of disorders that occurs in the microcirculation of the body&#146;s organs, including atypical hemolytic uremic syndrome
(the lead indication for OMS721), hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Omeros submitted a European Clinical Trial Application (CTA) in May 2013 to seek approval to initiate clinical trials evaluating OMS721 in Europe,
and a clinical trial evaluating OMS721 began in July 2013. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completed a registered direct offering of 3,903,004 shares of its common stock at a price of $4.14 per share. Omeros received net proceeds from the
offering of approximately $16.1 million, after deducting offering expenses. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis, or MS, further
advancing the Company&#146;s development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor, or GPCR, unlocked by Omeros, significantly
improved function from experimental autoimmune encephalomyelitis in mice. Using its proprietary high-throughput Cellular Redistribution Assay, Omeros believes that it alone has identified compounds that functionally interact with GPR17 and has
patents pending that are broadly directed to any such compounds active at the receptor. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Omeros Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system.
The Company&#146;s most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery&#153; platform designed to improve clinical outcomes of patients
undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding
compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the
Securities Exchange Act of 1934, which are subject to the &#147;safe harbor&#148; created by those sections for such statements. These statements include, but are not limited to, the submission date for the OMS302 Marketing Authorization
Application; when it will be able to market and sell OMS302 in the United States and in the European Union; Omeros&#146; expectations that it will advance OMS824 into Phase 2 clinical programs for Huntington&#146;s disease and schizophrenia this
year; the potential benefits of its potential products; the potential for GPR17-targeting compounds to treat nervous system disorders, such as MS; and its capability, through its GPCR program, to add a large number of new drug targets and their
corresponding compounds to the market. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros&#146; actual results could differ
materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in the Company&#146;s Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission on August&nbsp;9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no
obligation to update these forward-looking statements publicly, even if new information becomes available in the future. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact:
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jennifer Cook Williams </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cook
Williams Communications, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor and Media Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">360.668.3701 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">jennifer@cwcomm.org </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OMEROS CORPORATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands, except share and per share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investment income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income, (expense) net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average shares used to compute basic and diluted net loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,199,739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,466,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,053,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,450,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OMEROS CORPORATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED BALANCE SHEET DATA </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents and short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(238,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(214,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shareholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g581986image-header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g581986image-header.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`9P"<`P$1``(1`0,1`?_$`+$``0`#`0$!`0$`````
M```````("0H'!@4"!`$!``,!`0$!`0````````````8'"`4$`PD!$```!@$#
M`P,$`0(%`@<````!`@,$!08'`!$($A,)(105,2(6%PI!(U$R0C,D0R5AD29V
MMC<8$0`"`0($!`,%!0(*"@,!```!`@,1!``2!08A,1,'02(446$R%0AQ@4)2
M(Y&AL=%B<H(S4R0T%L&2HK+"8W.#PT3A)747_]H`#`,!``(1`Q$`/P#?QIAA
MIAAIAAIAAIAAIAAIAAIACP=>R73K3<[Y08263>6C&JE>2MS`@!_VX]GC3RL2
M4#@805%1HF/7M_MG#I'UU&M+W=H.LZ_J6V=.G$FL:08!<H/P&XC,D?'QJH-?
MRG@>.)!J6U]:TG1-/W#?PE-*U03&W?\`.('$<G#PHQ%/:.(X8]YJ2XC^&F&&
MF&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&.:9CR;#8;Q?=\
MFSX@,=3X%W)@W'K`S^0V*VB(I,4RG."LM+.$&Q!V'I,J`CZ`(ZB._-WV&PMG
M:CN_4O\`"V-LTF7CYW^&*,4J:R2%$'L+5Y8E&R]K7N]=U6.UM/\`\3>W"I7A
MY$^*20UIPCC#.?:%ISQGSX)9PLL/RFGLEW::!&!R$5^VRO./3'".3D[K8F3:
MH&,?8Q4EQNSYLV:E_P"DR.N/HDFH)?S!^F_N)JUAWEN=W;@N,NFZH'74IGKD
M$EW.BVO'C1O5O''&/PQ&0\$1B/T6[_;#TN][3V^U]"@S:AIQ1K"):9REM"S7
M'VCTJN[G\4HC'%F4'2OK];,?F#AIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAA
MIAAIAAIAAIAAIAAIABD[RQYJ*JK1./D3(@DDJ9+(%_[1R;)MDC+M:I&+B`@(
M&$Z;M\9(PAN*;8VWJ77Y[_6QW`#OIO:^QERH2+V]H>2BJVT;?>))BIYE8CXC
M&YOI"V.42_[BWD56`-I:5'-C1KAQ]QCB##D#*/;B%^>\"73"O&7"TRX0%K%Y
M5L\A<+KVFRC60B)_X)N7&=>?K!_F;1=8/)N$1'I$7SA<P@`@0=4#W*[:;@[?
M]H=OW\JY+/6KQ[J[HI5XINBOH('/Y8[<W#KRK,\AI7+B[^WW<'1-\=TM<LHV
MSW>D6J6]M5@R21=4^MF0?F><0(W/])(P#3-BQ2@^4K$-?PO03WQ*WV/*S>MH
MQ]I@Z[#`<AYF'$T:,D[FY=W&Q1"V!)L5Z':47,GWQ*8H"&VM4;:^LG8VF;`T
MQMR+?7>]%M`EQ#!%7]6+]/J-+*T<8ZX42^5G*YZ$`C&;-P_2?O+4=[ZBNWS9
M6VT6NB\$LTE/TY//D6*-7D_1+&/S!0<M02#BS;&EY8Y-Q]2\AQC-W'1]UK4/
M96;!\*1GC-"79(O4VSDR!CHG61!7I,)!$HB&X>FM>;1W';;OVOI^Z;.-XK74
M+2*X5'IF594#A6RD@D5H2#0^&,M[HT&XVMN.^VW=.DES8W4D#.E<K&-BI9:T
M-#2HKQ]N/;ZD6.#AIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIACY,
M_.1M8@IJR3+@&D/7XF1FY5T8!$&T=%-%GSU<2AZF[39`QMOJ.VO#J>HVFD:;
M<:M?MDL;6!Y9&_*D:EW/W*"<>S3K"ZU74(-,LESWMS,D4:_F>1@BC[V(&,X6
M#*?*\UN7"E_MC,30<W:)7(<\BX%9^W0I<`X8Q]=JBR)1(1J@1%LDQ*<QS"=0
MO^78INK\HNW.A7OU!=\#N;6X_P#ZZXO)+V8-5U%K"R)!;$<`H`580235ARH#
M7],=^ZU:=CNSHV]H[_W^"TCLXB*(3<S!GFN`>)8DLTI``H#SJ13WWD:Y1O,E
MVYW@>G$04I%0F4VK\[<I5%9VV1*ID%U2`F82D90[D#MVH%^TX@HJ.X"GT2?Z
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M/%`+B0?RL5*/6[%L3K*=)J"QP'[T]_31X^JW5NUN\;WMY)I%C<;*T6^ELH%@
M:2*YCM[=S%'YG>2.1U114%8PQKYEKPH,_31IG<C:EGON/5+R#=VKV<5Y,TRI
M+;O/.@DDX(D<D:EF-"&DRC\+4Q<7B3+=%S?18C(F/)8):O2Y5$_[B?MY&+D&
M_25]#3+$3'4CY:/4,!54C"(;"!R&.F<AS;PV/O?;G</;D&Z=K3]?2YZCB,KQ
MNOQQ2IQ*2(>#*:^#*65E8XLWAL_7]B:_-MO<D/1U*&AX&J2(?@DC;D\;CBK#
MW@@,&4=*U+<1C#3##3##3##3##3##3##3##3##3##3##3##3##3#$`?(KEPU
M`P@6C13Q)G:,PR85-BY46[/Q5;9=F2N-@.80$OMXZ,*1$^_H'N@-L8"B4<R?
M53O<[9[>#;EE(L>LZ]-Z9&)ITX$I)=3'^2D=%/LZE>-*'0_TU[.&X=]G7KM"
M^E:+%ZAE`KU)FJEM"/>[U8>WITJ*UQ\OA1B&4Q-QZL-T=1*D1:;G!/YJ`CW!
M$_D8NI1L4Y/26SPR:8+%D)%`P/G)#AW"K.-C%*8HE#Q_3YL:\V3VNNMP2P&#
M6=0MGEA0@9X[:.-C:*U!7/(/UG!&8,]"`P('K[Y[RM-W]Q[;1(IA-I-C<)%,
MXKD>X>1?4E:FF1#^DA'`JE02"":T.#V'XS(O)&H.+>W1D20,:ME"03=$4.O)
MS,05H1,'P.DDR+()VJ6254`J?0M[8`'T$P!D?Z=MB6FZN[%C)KJK*MM"=0<,
M"6DEB"TSY@`0+F56:@HW3H>9`U#WXWG=;:[97D>C,T37$HL4*D`)')F)R922
M#Z>-E%35<]1R!/R^?^/)7CGRL:Y0IY_AV=VDV66*B^*(I(,KK%23=Q9V13[$
M((_.)IO3D#_I2/3]-]>/ZF]K7O:KO0F\-"/0@U"9-2MG'`)=QR*;A*\!_7!9
M2/RSTQZ_IXW):=RNTC;5UD=::QB;3[A>9:VD0B!J<_ZHF('\T-<7.-\=<>N9
MV&:O>+!0ZY*,[_7&TPE.,&;1C:X"7<HF2DTF5E9(IR:$E"RY%D5`,<Z1U41!
M0AR[E'?46U>UW?[8-GN+4]-M)H-3M%E$R*J7,,K"D@2X0"0212AD:I*EE(=6
M%0<22;D[C]D=[W>@Z?J%S%-IURT9B=F:WFC4U0M`Q*%)8\K"@#!6\K*>.(>\
M"*/:^/G)WDEQPD)-67K49`5Z[1#XY033>HJO6[:#F!0(8R+21DX&9(B\*3[1
M78[!N4A=43]-&W=:[7]W]V=J+J9I])AMH+N)SP#@LJPRT'!7DAE"R@<,\-.2
MC%S_`%!Z]I'<;M9MCN9;1"'4Y;B:UD7F5(5FECKS9$EB+1D\<LM>;'%O>MSX
MQKAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIABKQ_AU+F+R:F,C6ERF\
MPO@^P.<;1->5(\]M;I.$(1]9#)+E229N(]Q9S)I/!3.H1PS1(@<=^HA<=7.P
MT[\=WI]U:RX?8&W;IK".`ALMS)$`\]#0*R-<$++E+!XD6,FM0-66^]&[+=K8
M=M:2A3>^O6RWLDP*YK=)3DAJ*E@X@JT=0I21C(!2C&S_`+*/9]OVD^QV^SV0
M(4$NST]':!,`Z03Z/3;;;;6PNFG3Z5!TZ4I3A3E2GLIPIC*N=\_4J>I6M:\:
M\ZU]M?'%7^(\3,./G*U-BLF=&(G8FQ1%7DG"J@G5A9MXA*QS,K<G6F+=O*IB
MT47,(F*H1`B@AUE$<>['V3;=K^]0MG!6QN8)XK>1B:F*9A)&H45&42`Q,Y)(
M81*U,P)U7O'=]QW&[1FX0AKRWFADG10*"6)3&[5/',8SU`@`!4R,M<I&+)IR
MK5BSE;$LM<@;"1D94[,LY$1\L5H=<"%6,V*_;N`0,L5,H&$NPF`H;_0-:SU'
M1M'U@(NK6EM=+&25$T2292:5RYU:E:"M*5H*XS%8:MJNE%CIES<6Q<#-TI'C
MS4K3-D(K2II7E4X\1=[_`(DX^4YO-W&4K^-Z4$JC$M5$8P[2+++2@.WB;5!A
M",%>E=Y[9901*EL82F$1W'UCNXMS[([8:"FH:]-:Z3M_K"-2(RL?4DS,%"1(
M>+96;@O$@DFN.[H.W=X=QM::QT6*XU/7.B9&!<-)TX\JEB\KC@M5'%N%0!B#
MV,^57$F,R1EG,]CS34VEHR:O7(>-C1:6`Z]>H%+8'85Z/=*%A3%^8F7SEU)/
MB$,8J!G"2&XB@)C9WVAWG[(VF[-;W]JNX+)-9U=H(HX\LY,%E:(4@1CTJ=65
MVDGF`)"%TCJ3&6-\;H[2]X;K;.C[(TW0[Q])TM9I'?-"!-=W+AYG4=7^KC58
MX8B0"P1Y.`DH)>8ZY/X'RU*JPN.,AQULDD$".5V\=&SY2H(J*"DF==PZB6[5
M'N*`)2@8X"(_0-7CM7O#VVWO>-I^U-4BO;M5#%8XYN`)H"6:)5%3P%34XIO<
MO:KN!L^T%]N739+.U9BH+O#Q(%2`%D+&@XF@X8[UJR\5]AIAAIAAIAAIAAIA
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M\@ZE3CVC`%<I%WEX<B[B:I=I9S9Y:88$*!^Y5'<5.1:*DJU`IA]FL01=%'9(
MX*`5-2$]U-3[GZ)H)UCME::=J-]`"TMI<+*9)4'&MLT<T8,B\?TG!Z@X(P<!
M7E_;;3NW6L:T-*[B7-]86<Q`BN8&BZ<;^RX62*0B-N'ZBG],\74J2RTC7+R<
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MF+N",H3&(2)"P8]-4&4\`0%8*/RXFGS=X_W'DEAQCCZCR5>BYEM>8"RJ.;,Y
MD&L<+",8S31PF52-CI-P+H3R1!*7M@40*;<P#MOH#ZA^V.O=V=AQ;7V[+:PW
MZ:E#<%KAG5,D:2JP!C21LU9`0,M*`\1PQ1_8GN)HO;'>DFX]>BN9;)K":`+`
MJ,^=VB931W09?(:G-7B.&*X*+XGLF1-C8NKM:,5V*O%7$C]DUD+HBX,S,@J4
MQT4BUYH"K@%C$$H>X1Z0*(@?<=90VY]%&[K+58YMPWFBW6EAJ.BO=!BI4\0.
MBM6K2@SK2G!L:9U_ZO-KW>F21:'::M;:D5\C,EL1FJ.!/6:@I6OD:M>*XM_Q
M7@O'6(89M#T^O,8U)$4U3^V%^*)W16Y6YW`(/I"0Z3F*7TW,(E_I]-];IV9V
MYVKL;3TL-"M8XD6A.7/0ME"EJ.[\3]O#&,]V[^W+O*]:]UFYDE9J@9LE0M:@
M51$X?=QQV+4\Q"\-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,<3L
MG&SC_<9R0LUIPUCB>L$LL#B4F9.I0[J1D'!4RI>X>.E&HJN%Q3(`"<XB8VWJ
M(ZKW5NTW;'7M1EU?6=`TFYU2=LTDLEM$SNU`,SL5JQH!Q/$^.)UI?<[N)HMA
M'I>DZWJ=OIT*TCC2XD5$%:T50U%%2>`X#']M-X_X1QW.)V:BXIHE2L*+5RR2
MFH"MQD9))M'@$*[;$=M4$U2HN`3*!R[[&V#?7HT#MCV\VMJ(U?;>BZ;8ZHJ,
M@EA@CCD"O3,H95!HU!4>-,?#6^XF^]R6!TO7]7U"\TTNK&*:9W0LM<K96)%1
M4T/ACK^IUB&8:88:88:88:88:88:88:88:88:88:88X+R5Y,89XCXBL>;L[W
M!K3J'7`10,X,DJ]EIR:>@H$56*Q#-@,]G;),*I&*W:HE$=BG44%-%-50G7T/
M0]3W%J*:7I,9ENW^X*HYLQY*H\2?<!4D`\3<.XM)VOI<FL:U*(K*/QYEF-:(
M@YLQH:#P`+$A02*RJSY3N2F2./-SY88M\:F7+%@V#6A)>E*SF5J77LE9/QN<
MEE6N&1*YCIM#3DB2.J[>+8JH-TU7@RZ3XYVBAR(&,:<S[!T2RUF+;U_K=NFK
M-F5PL3M'%)Y<D;2%E%6JU2<N0K1@"1BN[?N3N#4-"EW/INW[F31$RLA:9%EE
MBHYDD6((S43*M`N<.&JK$*3B9_!/R!\?/(1B]WD;!\M)-I&NN649?\=VE!M'
MW>@S#YN=PS0F631V]9O(J4305,PD6BRS1X5)0"F*LDLBE&=V;/UC9U^++554
MHX)CD2I20#G0D`@CAF4@$5'@03+=E[ZT+?6G&_T9V$D9`EB>@DC8UIF`)!!H
M<K`D&A'!E91YGR0>0"L^.7"U5S1:L;6+*$;:,F1&-BP=9FXJ"?LG$M7K/80E
MCN9=%9LN@@C6#I=H.DQCK%'J``$=??9.SY]ZZG)IEO.D$D<!ES,I8&C(M*`C
M\U:^['F[@[[M>W^DPZO>0//#+<B&BL%*U21\QJ#4>2E`*U(\,25XV<A,=\JL
M&XWY`XI>NGE%R;7TYR()(HIMI:,73<.(Z8@)IJBLX1:S=>FF3AB[3(HHF5PW
M/T'.3I,/#US1KW;^JSZ/J``NX'RFG(B@*LO+RLI#"H!H>(!X8D6WM>L-S:-;
MZ[IA)L[A,PK2JD$JRM0D9D8%6H2*@T)%#B"ODR\L>)?&B7%K"Y4&T94MN4BV
M:1856HS$+#NX6MU<C!)U8)9U,]:96[Z4DTVK5,I1,L=-8VX`D(#*]C]O=1WO
MZB2UE2"WM\H+."<S-6B@#V`5/LJ/;B&]P>YVD]OFM8;V)Y[FZ+452!E52HS,
M:'F6\HIQRMQX<;+<?VQ*^T.DWI!BM&(72HUNV(QKE5)PXCDK'#,IA-BNNALB
MLLT(\!,QR?:8Q1$/0=0B\MS9W<MH2&,4C)4<CE8K7[Z8L"PNQ?V,-\JE5FA2
M2AXD9U#4)'.E:8JRY2>7&E8CY#Q7#?C;ABY\QN6$BJ9O)XVQ].1-8J])<%8C
M)N&MVR!*MI)A%/HN,V=OTR-E4(YMZO%VQ]B#/=![=W6HZ.VY=;N8M-V^.4DB
MEF<5I5(P02">"\06/PJPXXK;<O=*TTO75VIMZTEU;<YK6&-@B(0*T>4A@I`X
MMY<J@'.RD$#N^`N4O*NSY1A,4<G^"=QX_KVF&FY6M90IF5:9G7$*CR":^_<U
MRUV&MM8.6H\^]9%4,Q([9J(OCI'*FIN&N3K&@[?@L6U#0=6CO%C90T3Q/!-1
MC0,BL6$B@TS4-5',8[6A;EW-<Z@FF[ET66P>56*2QS)<PDJ,Q5W0+TV('E##
MS'@,<Z\F?E$I7C/C<.2MUQ+;\HM<P2-VCV?XG.P4,I!'I+6LNW)WA)HH^\]^
ME9"]H$]ND43=0_<77MV-L.ZWP]S':W$<#6P0G.K-FSY^5.5,G'[<>#N)W(LN
MWB6CWMM)<+=F0#*P7*8^GSJ#6O4X>'`U/+$<\L^;13B_8L=M^8/!GD3@&@Y.
M(BM6<H-[%C'*=77;+(-WBBAE*-87*:CJ/8.B.'3!-8\H1#<R;57;8>UI_:\:
M[%,=MZK9WEW!\4666)J\1^-:\2*!B,A/-AB/ZEWA.W)+<[LT:^L+.Y^"7/%,
MM#0U)C.7@""5#EP/PGA6[&FW"KY"J59OE(G8ZSTZY0,59ZM8HA<KJ,G("<9(
MR43*L%R[`JU?,7!%"#L`[&]0`=PU5]S;3V=Q):72-'<Q.5=3P*LIH0?>"*8N
M&SN[:_M8[ZR=9+29%='4U#*PJK`^P@UQ7YSE\GN$>$T[2L6KUZX9PY)917CF
MN->/&*6[:1N\\K,2`14.[FG"YQ:UF+EI(#(-#J$7=NU2']NV5(DL=.8;5V)J
MFZ(9;\/':Z)`"9+B7@BY14A1^(@<3Q``YL*BL&WEW&T;:$\.F,DEWK]R0(K:
M'B[9CE4L>.4,W!>#,QKE4T)$><Z^6?*/#LN&+1S+X*Y(Q)B3*L3%HV#)=&R7
M3\O-\5Y`D9&Q=R@6N'@XZ*]X]:5R+:R0+H.BF=%671:HN%FJA1[&E=O;#<AN
M8-LZK#<ZC;L<L;Q/#U8P%_40L30%B5H1PH"Q4,,<'6>Y^I;4%I<[MT:>TTNY
M50TL<R3=&0LWZ;A545"`.3F%06"ABAQ;YCW(5)RQ1ZKDK&]FB;E0[O!L+'5+
M1!N2NXJ:A9-`KAF]:K`!3%ZB&V.F<I%45"F34*4Y3%"N;RSNM/NI+&]C:*[B
M<JZL*%6','^/D1Q'#%J6%]9ZG9Q:AI\BRV4R!D=>3*>1_C!H0:@@$$8@#SB\
MHF$N%MIIN'B5B[9ZY-9+%@3'G'?$;)&3N<L,N\/'P[J>>*B9I6H^7>)*)M>I
M-R]<]LYTFRB2:BA)?M;8>J;GMY=2+Q6FAP5ZEQ*:(*"I"CFQ`XGB%'BP)`Q!
M]X]Q]'VE=0Z1TY;S<-Q3I6T(JYS&BECQRACP%`SGP0CCB1W';*?(BZ8HG;YR
M9X[L./MN:.I.2AL:UK)L;F"8<5%O$MY%B>5DH:%@X]G;E7'?;J,$!<I@8A!!
M;<YB$XNLZ?HUKJ"6FAWIO+8@!I6B,*YR2#0,S$I2AS&GCPX5/>T#4]>O-+>^
MW%8"PN@2RPK,L[9`H/F*JH#UJ,HJ.`-020/(<8.5DKGZQVZO2]':5@T,Q)/0
MSZ*FUIMF]@G#EJV:+.5EXZ/[K>0%W_P)!$OM9([1\5(A/9G$_IU[;T>CP1S1
MRF3,<K`KE(:A)\3Q%/,IXK5*_$*>+;.Z9=>N);>:`19%S*5;,"I(`K4#@:^5
MQY7RN`!D-9H:C&)EAIAC$WYY\GV'E)Y,>.'!)G)NT:)39K$%5D(ILL8$7.0\
M^V"&"9G5DTQ`JKJ*H,K&H-1/N9OW7/2(=XX#J+M)80Z#L:]W8R@W<B3."?[.
M!6HH^UPY/M\OL&,<][]4GW)W&T[9*.PLHGAC(']K<,A+'P-$:("HJM&I\1QM
M,KU?AJG`0=6KD<UAZ]6H>,K\#$,4BH,HN&AF2$=%QS-$NQ46K%BV(DF4/0I"
M@&LQ332W$SW$[%II&+,3S+,:DGWDFN-@6]O#:P):VZA+>-`BJ.`55`"@#V``
M`8Q)<6Y\_`G^0]D?"M3$T)B_+V7K5BU]6&AA1BRUS,<*VR;C5FBU#^R!:Q;Y
M:-0:FVZDFPJIE$`4,`ZCU^$;N[-0:I<>:_MK=)0QYYH28Y23S\R!R?::'P&,
M;[:N/\D=^[C1;0Y--NKEXF3DH6<"2%0.7E9H@#2N4$>)Q;W_`"-Z-*9+XC\>
M\?0!4S6.]<T<14JO`L8Q4!FK=4\E0$8182[B":CU^F41V'8!WU7/92[CL=QW
MMY-_40Z7,[?S4>)C^X8M3ZA+&;4]JZ?I]N*W$^L0QK_.>.91^\XC_P#QB\\N
MI/"O(/BA9U3M;)A+)!+Q!Q+TQB/6M;R`5Q%V.,30..Y$X"\U9RHN``'0M*@`
M_778[[:0L>J6>X+>A@NH<C$<BT?%3_21P![DQQ/INUR271;[;%U47-G.)%!X
M$)(,K*!_)=,Q]\F*0O.YD2T<@^8^<,M-%#.<0X3O$7PXISPRIE$%[;1*F_NF
M0F[#I`4#`RMDP^%<Q1WZ5FX#O_2TNT]G;Z-MFVTYN&I7437CCV)(P2,GQXH%
MI[PV*=[U7EWKV\KC5DH=)L[A+)#7F\53**<JK*7)]S+C;?<<R(\<_'G(YQ!)
M$ZF)>)K2[1C58O4W<R]?Q:V>0,>H01#=)[+I((B'^!]9<MM-.M;R&E$FEQJ)
M0GV!I2&/W+4XV+=:M\@V"=94`O:Z4)%'M98047[VH/OQG=_C`X_/>;IS.Y4W
MA=:QY&D)*I48MIE!%W)N7UT>SV1,E2"KQ83*B\L,LA$JKF^IA2]?0=M7-WWO
M!:6NF;?M0$LU5WR#@`$"QQBGL4%P,4']-UB;Z\U?=%X3)>NR1AVXL>HSO*2?
M$L5C)/B:GQQKZUG#&KL9*/Y6)2_@'"X^WW%M^<2`/^!3UW'AC!_AZBF7_P`M
M:'^G_P#QFIC_`)<'\,N,M?4V!Z+1SXB6?_P8EKY]QJH>(ZMC8`:#,?FG'G\'
M%QT>X+9?:F%\+`3?<"_X6$L!^GU[`J;^F^H]VA]1_P#T5^C7I=*XZE/RUX5]
MV?)]],2COD+4]JH_49>MU+?I5YY\AK3W]//]U<3'\."<_C[Q2<6I#)0NXT8G
M%]IMXC(E4*X94-[<;C:JFN8JP$.#7\'=LUD`'T*V,0`]`#4:[E=&\[@7Z6-#
MFG1.'C($1''VYP0??7$N[3>HL.V6G2ZF2"L$DA)_LS+(Z'[.F5(_DTQGP\)<
MU*\[/+SG_F/E+JF9BLTV]Y+K*+_=XC7'URGHK'E`AV`+BH#=K4,;.WC%F`>J
M8)%,'W_=JXNZ,4>T^W-GMJP\L<DD<;4X9@BF21C[WD"L?;4XH?LY--O;NM?;
MMU,9I(HI94#<<C,RQ(H]R1NRKX@*O'AC4!Y-,+PV?>`_*O'4NS0=JJ8;N-MK
MQE42*J,KACZ+6O51?-3&*)T5T;!7FX=1-C"F8Q=^DP@-$;%U.72-W:?>QD@>
MI1&]Z2'IN/\`58_?3&D>X^D0ZWL;4[&50Q]))(M?[2(=5/\`:0`T\"1XXI0_
MB[\AYJXX)SUQQG9%9XSPY;ZW?*(BX4.J:.K&5D)OYR&9]1A!&.96RKKO0(``
M`+RJH_ZM6AWYT:*VU:SUN)0&NHF1_>T67*Q]Y5POV(,4[]->O376BWVW)V+"
MRF5XZ^"RY@RCW!DS?SI&/CB&6/<PU[#?\EG*]HY+/DXAM,Y(O&.Z;9K6<J,?
M5%+ICV(A,,R)G;L01CHF1JRS6*0<")442R8'.8I.LP2:\TV?4^Q]O!H8+%8$
MD=4YODD+3"@YD.&8CF2M!QIB)6&KVVD?4/<S[B(7/<21QN_*//&5@))Y`QE$
M!Y!6!-`"<;9M9=QL7'Q8BMUVOF?G@8&%A#RKL[^4/$1;&--)/E!,8[U^9D@B
M+QV<3B(J*=1Q$1]?77UDGFFH)G9PHH*DF@]@KR'N&/C#;V]N6,$:(7-6RJ!4
M^TT`J?><?:U\L?;#3#&$[F*Q6@/Y*-&<3H@BTD>4/#V8:+./]H\<^K6*&;)0
MHF].V5ZW,F']"G(/^&M9;:<3=D)5AXNMA>`_:&F)_=C$>[8S;_43"]QPC?4[
M`@GV%;:G[^&-V.LFXVYC"-R$%;(/\EVN-JV!G"T;RTXY(+F;]2ADR8^I&.9"
MSJCT#N7V#6!=BI].D$AW_KK66C4L^QSF?@&T^YY_\QY0O[<P_;C$>O*]_P#4
M6@M^)74[0\/9$L&?]F1J_9C0=YM#F3Q_P,.01*<GDUXGG*8/J4Q7UM$HA_X@
M(:ISM=_B]7__``KK_@Q?G>$TL]#(Y_YBM/X)<4I/)N;\8WGWRT6`CNJF<F8.
M]2U6@P$L?&V!SG2!>W:FPJ/6*;5!NER.K9(@AO0J*)C;;;[#:*Q1;Z[16_6;
M^\V+QAVYE1`P1V]M?3,7/M-,4W)/-VW[Y7704>DU%)&1:T#FX4R1J!R`]4%C
M'L5#3V8BIY&L%3V#_$SX]7EX1=IY2SUEW-7)?*ZL@0Z4BZN>9ZI&V5`9))4`
M62D&-2-&-5R*?>19`X#L/IKO;*U6+5.X.LI:T]#:6T-M$!R"0LRFGN+YR/<1
MCA;_`-%ET;MKH3W53J%[=S74K$4+--TBI8<PW2$8:O',#C47Y!8N2F/"UFAG
M%$4.Z3X?U62.5(HF.,?#5ZJS$L.P>O06*8K";_`H#JA]GR)'W.MFD^$ZBX^]
MF=1^\C&C=[QO)VBN1'S&EQ,?YJK&S?[(.*'/`G@#*7(GCAG6"Q+R\RWQ1DZ7
MGF.F+&ZQ-$5&6<W6/LV.()C#-ITMK8OBH-X9S779VPH=`F,NIU[[%VMGN[J]
MAH^N6LNH:=;W\<MJ0O5+#(5D);+E_-F6M?8*8I/L1HVH:WMN[ATW4KC3Y(;H
M%ND`<X=1ES5(/ER-3C3S-4'A32AQ?X;Y^P/E!W?<F^0#D#R=KCFHRE=3QOE"
M%IT96F<J_D(9XUM3<]8;LE/E(UM&*MTRG3,04W:@[@.VJ1UW<FD:K8"TL=(M
M+&82!NI$S%B`&!3S>!)!/'P&-$[?VMK6CZB;V_UF[OK?I,O2D%%J2I#\'/%<
MI`X?B/'%&O\`*Q_^ON%__O+-W_QS'^K6^G__`!FI_P#3@_WI<4E]3?\`@=(_
MZL__`(,<+\E4Y/UCR3\&Z_SGD'F6/'Q:8?&MDQ]CQ^<:S2:>A-U^)I%U7L*M
M73B'-K?T&Y+M)9Z>05<JKUYV1H<>VJJ4_6V1##<;(U6;:BBWWC&TBR2#S.^5
MBZ9<V8()$JBY:`2`MS`QQ.X5Q<6O<+18-YL;G8LB1/%$3DCC#(J2%BA4N8G_
M`%&+5)CRI7S'&N#.5>]WQVS#4ZJR;L_=86R#7JY'1;=)LT:]ZC2\;#LHYJT*
MFBW;H=29$4TBE*0H`!0``#6=M)FRZU;7%P2:74;,3Q)_4!8DGF>=:XU-K=OF
MV]=VMJH%;*5$"B@'Z3!0`.0'``#&0W^*NLT3S9RP:*"4LBIB#&2R"8^B@M&U
MMGDGHAOL/2FNY0`WI]1#6C._P;Y7IS#X!<25^W(*?P'&5_IG9#K6K"OF,*D?
M9U./\*XUO\JYIG6^+_(^PR!TTV,'@;+TL[.J)03!O'X_L+M7JZ_L$!(D(;#]
M?IK.VWXFGUZQA3XWNX0/M,BC&H]TS);;9U&XDX(EC.Q^P1.<9.?XJ=>E5,F<
MO+25)4(2/QUB&N.5ND>P:7E)ZY235$3;;"LDSAUC;`/H4_K]0UH7O_-&+#38
M.'5:65A[:*J`_O88S!],L,C:GK%R*]%8XQ7PJ[N1^Y&Q:?YH?$`PYTUHV=\)
M),87E-0ZT:/+'+BBTA\V52*!=TSILTZ.)$HZW1O=5+"R2@]H>Y[-V((&17:0
M#MCW'?:D_P`IU0EM`F>M>9A8\"X'BA_&O/\`$O&H:R^[_:B/>UM\ZT>B;E@3
M@.0G5>(0GPD')&/`_`_#*R1M_CY>1[*N8U;EP7Y&/9>:R#AFJN9W&EJL_N0N
M"U0JTRQJMHQS=E'H^]>SM$D)%H#-=?=V9F95!<1%J0Q^WWBV3I^F"+=>BA5L
M[J0+*BTR9V!99$IP"N`<P'#-0CXCB.]A^X>J:N9=E;A+-J-G$6B=JYRB,$:-
MZ\:IF7)7S9<P-`HQJ%U0^-*8:88:88RC?R%N%65&V0,0>2+`%=?S\WAY*L,,
MN,(-DN]E(1''UF&W8ZR:HQ9E4=O(:*>+K1\PJF43,VQ6BI@[!%U$M!=G-T:>
M;.YV3K#A(KG,82QH&ZBY)(JG@"0`R#\1+#G0',/?C9VIB_M.X.AHSS6F03!1
M4ITV+1S91S`KE<_A"QD^7,RVVU7S&<#)SBDVY32F><?0C)"GIS$_BQ>U0ILM
M1ER3CBK/<<-J$9XG8Y*R#+[M&QTFXM')1*Y*K[416"NKCMMNR+7SH,=I,Y,F
M59LC=$I6@D,E,H6G$@FH^&F;ABU;7NOLN?;8W!)>0(XBS-;YU]0),M3$(JYR
MU>`(&4CSUR>;%.OA!X>9<SQRNRSY9.152?5)G>['D:QX.@IMJJU>SMBR@_D"
MSUVCFCQ)-P%.JE3D5H6)<F(4D@=RHJB/;;%,I97=/<NG:3MZW[>Z+()&B2-9
MV4U"K$!E0D<,[.`[C\-*'XN%2=F]HZIK6Z+KNAK\1C6:25[96YL\Q;-(M0#T
MU1F1#3S9N%,AK8]YOG((T7@$D8Z9"N/)MQ7(/6(`)C)KV]0A2"(A]PB'T^HA
MJ$]K16ZU@^S0KK_@Q87>,GTFA`>.XK3]RRG_`.<<5\U_!*P<E.0/CAR90DY!
MA/!R$K^$+W8X<%`DH&D2DA^T(VTE61(8[4M,)2IQ1)4?M*Y?IAZ"8-^KVOW9
M#HFCZU8W=&A]&T\:MR9P.D4IXYR\8(]BG'&[P[*FW!KN@:E99EG]<MM(R_$J
M,3(KUI4"(+,U>69@.9&(P?RKUVS?"?$5N<Z:(GR9D\Z11$J9.VA2(DAP+N(`
M'0*Q=@#^@Z[G8&OS/4F/+H1?[S?Q8X/U)@MI>E1H"6]3(:`>`Z0_TC&C3'=/
MKN5^)%$H-L:$D:GD?CI5JE9&29P$CR`MV-6$1+-TE=C@`+Q\@H4I]AVW`=4Q
M>W,VG;CFO+<Y;B"]=U/L9)20?VC%[Z?9V^J[3@L+L9K6YTY(W'M22$*P^\$X
MRG^,ZS27A6Y]YPXD\QI+]?X@SRPBR8SS=8$E(['%E?TB4F#8^MQK"L'QD?%6
M>N6-XRDSG4_[/+D20=BDGU*EO_?,,?<_:%IN';:];4K0GJ0+QD4.!U$R\RRL
MJE13SI4K4D`YG[<RR]H-\7VV=UMT=)O5!BN&X1,8V8QO7X51E=PQKY&*JY&5
MB-45?YF\5[CEFKX,HN><9Y"RK;X:;L<54,>6F+O3UO7JZR]]*3<XZJJ\M&UR
M/(F=,B)GZS<SI14I404'?:@IMLZ_:Z?)JEW:3PV$;*I>1#&"S&@"AZ%C[<H-
M/&F-,6^[=M7FI1Z38WMO<:A*K$)$XEH%4L2Q3,J"@X9B"WX:XS=?RMG:*-&X
M5(*K(IBI:<[K@"BA2'$&\!C5,3%`Q@W(7W/W#MZ"(:NOZ?Q_>M4;P$<'\,O\
M6,^_4T&>UT:-!5C)<&@XGAZ?^/$Z_-9Q+1Y.^,&+N]?C`DL@\:ZC6LT5=5NB
M*KQY3V=49-<I0J)B_?[1W3#'DQ(`"*CB(;AJ*=K]PG0M]M:3-2SOI&A<'D'+
MDQ'[<_D]P<XF/>#:XW'VW2]MQ6_TZ)+A#XY`B]85H>&2DA`YF-1CN7A#YH->
M8_!BBEGII"6RO@Q)KAG**:KE)Q(/C5Z/1)2K<\3ZC+*IV^F@V45<'#9>2;O0
M`1%,VW*[I[9.V]US&%<NGW9,T5.0S'SH/#R/6@\%*>W'=[.;L.Z=EP+=$_-+
M(""4&N8A12-S7B<Z``MXR+)[,4;X]J;[P:^7N8LV4&$E!<*.2Y+G4:OE<C!V
M[JL!5+Q.,+A7XZ7>MT5$VLSBNW1C>/D4#;./A3F?IIG2.`:M6]N4[J]N%@L6
M5MT6.1WBJ`[.BE&(!_#*A+*>6>B$U!Q2^G6,O9KNLUQ?JR[0U'/&DH!**DA#
MJ#0'S1,BJ_CD#/2C*#95YF_(UAJ3XHS7%SB_D2L<@.0/+-O'8XJ]1PC.Q^3)
M5C2;"\;_`)3+/$J:XERI.)^%(I%,&AC%<N57XJD(**"QBP?MGLO4H]PKKVO0
MR6>D:>3(SSJ8@74>4#.!\+>=FY#+0D$C%B=V]_Z3-M=]N[9GBO\`6]3`B5+=
MA-2-C5RW3+?&H**OQ-F)`(4XEMX9^`\KP)XCL*S?VS5'-V69K]EY<1:K(NR5
M^1=1[:.K="3?MSJ-WI:;`MR$<*)F.B:3</#)'.D8AACW<S=T>[MQ-/:$G2[=
M>E#X9@#5I*'EG;E7CE"U`-<2?M%L:38VU5M;T`:O<MU9N1RDBBQU'`Y!Q-"1
MG9Z$BAQ.?D;RJX_<3*%*9&Y`92JF.J_&L'+ULVF)5J6Q6)1N4>F,J5:(J,W:
M)ATKLFDW9(JG$X^O24#&")Z+H&L;ANULM(@DFE8@$@'*M?%V^%`/$L1B;Z]N
M31-LV;7VM7$<,2J2`2,[T%:1H/,[>Y0??05.,\OA&XS9/RES%Y3^4N^X\E\2
MXYS?,91_1=1L#,\5,V!EE7(#>XRUG3CCD34_'X:'C&[))WT@A)/':ZC<3)H=
M9KE[I:[86&VK#85I,MQ>VJQ==U-0IBCR!:_F8G,1S4``\\4'V<VUJ.H;MU/N
M5>P-:V%Z\WIXV%"PFEZA>GY4`RAOA<M4?"<:GM4%C3&&F&&F&/PIV^VIWNCM
M=!N[W.GM]OI'K[G5]O1T[[[^FVOZ*UX<\?PTIQY8K%69^&G]L>\<'\:_[K"6
M$@D6?\9_V'\]WA*(BP.X^<&:]SO]W;]QW?7?J]=3H-W,^7Y5^>?*\OLN>GE^
MVF7+3WTIBN&3M%\TSM_EWYQG]MGU<_V5S9ONKBSA#L=A'VO:]MVD_;]CH['8
MZ`[79[?]OM=O;IZ?3;Z>FH*:U.:N:O'%CKERC+3+3A3E3'B;W^LNS7/V;^">
MW_*HC\1_._Q_L_F^ZOP7XY^0?9^5=7<]I[7_`)>_5V_ZZ]5IZZK^AZU>F<_3
MS?!^+-E_![:\/;CQ7WRVD?S+H4ZJ]/JY?ZSCER9OQ\\N7S<Z8]JM[?J0[_9Z
MN\'MN]T=7N.VIMV.OU[W:Z]NG[NG?^F^O*,W'+7EQ^S'L.7AFISX?;[O?CDV
M7/T'[.%_?'Z@^/\`</?QW]N?A?L_=]A+Y'X7\R_L>X]MT=[L?=T=/5Z;:Z.G
M?-\S?*?4YZ#-T<]:>&;)X<Z5QR]5^1Y4^=^DR5.3K].E>%<O4\>5:>ZN.GQ/
MQ7Q4;\'\?\)\>S^'^)]O\5\5[=/X_P"-]G_Q/C_:='9[7]OM[=/V[:\$G4ZC
M=6O5J<U:UK7C6O&M>=>-<=*+I=)>AEZ.49<M,N6G"E.%*<J<*<L<2Y%DXO*T
M,R?+(<$!C-1UT;\@U*"C2@?F1.`"FKD0Q(5-_P!D3=)BB"H%WV'74T4Z\+NN
MW?5^NI_Z_4ST_P"WYJ?NQQMPC;)L:;J]#\MK_P"UTNG7_N^6O[\<SXHM?'^T
M0G4.$9N(YTRD*-G-QE=XA?*]LRH"G^0.,9K.%S)=[;H!R82@;Z>NO=N!MWL4
M.Z?F/\CU(F'^J)?]&.?MA=BIU!L[Y57\?I#`3_3,-3^W'9,N_P#Y[[<'^^OT
MUV=Y+\:_;OX1V^KI9_,?!_F7V[]'M_<^W_IV^O\`TZYNG?.:O\H]37AFZ.?W
MTS9/OI7WTQUM5^0^3YYZ.G')U^G[LV7J?T:T]U?#'35_@/@%O<_#_BWPZGN.
M_P"R^`^`]D/=[W<_[=\/\=OU=7]GL_7[=>%>MUAES>HS<*5S9J_MS5^^N.BW
M0Z!S9/2Y.-:9<M/V9:?=3W8Y;B+_`/.O5._H7]*]7;C/R7]1?@W5VO\`G?#?
M._AOKV]_<^U]QZ?[O1_JU[]1^=>3YOZKQR];J>[-ES_=6GNKCFZ5_E^LGR/T
M=>&?H=/WY<W3_I4K[Z>./M9C#"XX_F@Y`_K#]6"5(+%^XAJ@4#IZA[/S(W3_
M`-/`'7_D[_\`7Z:^6F?-/6+\GZ_S#\/1S]3^CD\W[,?;5_D_H'^?>F^6?CZ^
M3I?TNIY/VXB]Q=:>,MG:)`G#,_"$]V.@Z/)CQQ?8.?6T&@DV>`[4QTX<31&?
M;_W"F$$]OJ&N]KS;Z:`'<WS7TM>'J1.$KX4ZGEK^_$9VTG;A+EAM#Y+ZVG'T
MAMB]*>/2):E/NIB>.HEB<8B?GMKP@5R-B-UR>-Q@#*C4TZ7!Q<YO,8(W0QW"
MT46P?K5G>UR2SQ4KDC+OC'$.9)7M"/282[R#2&W2+*Y70O7^@.7K]`2Y.%<O
M5,?`<*TS<Q7$8UQ=FF_M6W)\N^9`MZ?U)ASU-,W2$AJ3R^$$@XE:GV^VGV>C
IM=!>UV^GM]OI#H[?3]O1T[;;>FVN`:UX\\284IPY8_>OYC^X:88__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
